PL3271015T3 - Antagoniści receptora nk-3 do traktowania leczniczego lub kosmetycznego nadmiaru tłuszczu w ciele - Google Patents

Antagoniści receptora nk-3 do traktowania leczniczego lub kosmetycznego nadmiaru tłuszczu w ciele

Info

Publication number
PL3271015T3
PL3271015T3 PL16710199.7T PL16710199T PL3271015T3 PL 3271015 T3 PL3271015 T3 PL 3271015T3 PL 16710199 T PL16710199 T PL 16710199T PL 3271015 T3 PL3271015 T3 PL 3271015T3
Authority
PL
Poland
Prior art keywords
therapeutic
receptor antagonists
body fat
cosmetic treatment
excess body
Prior art date
Application number
PL16710199.7T
Other languages
English (en)
Inventor
Hamid Hoveyda
Graeme Fraser
Original Assignee
Ogeda N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ogeda N.V. filed Critical Ogeda N.V.
Publication of PL3271015T3 publication Critical patent/PL3271015T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
PL16710199.7T 2015-03-16 2016-03-16 Antagoniści receptora nk-3 do traktowania leczniczego lub kosmetycznego nadmiaru tłuszczu w ciele PL3271015T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15159296 2015-03-16
EP15193513 2015-11-06
PCT/EP2016/055735 WO2016146712A1 (en) 2015-03-16 2016-03-16 Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat

Publications (1)

Publication Number Publication Date
PL3271015T3 true PL3271015T3 (pl) 2024-03-11

Family

ID=55538244

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16710199.7T PL3271015T3 (pl) 2015-03-16 2016-03-16 Antagoniści receptora nk-3 do traktowania leczniczego lub kosmetycznego nadmiaru tłuszczu w ciele

Country Status (24)

Country Link
US (3) US10624890B2 (pl)
EP (1) EP3271015B8 (pl)
JP (1) JP6762312B2 (pl)
KR (2) KR20170124566A (pl)
CN (1) CN107405347B (pl)
AU (1) AU2016232191B2 (pl)
BR (1) BR112017019829A2 (pl)
CA (1) CA2977444A1 (pl)
DK (1) DK3271015T3 (pl)
EA (1) EA036709B1 (pl)
ES (1) ES2965675T3 (pl)
FI (1) FI3271015T3 (pl)
HR (1) HRP20231661T1 (pl)
HU (1) HUE064813T2 (pl)
IL (1) IL254386B (pl)
LT (1) LT3271015T (pl)
MX (1) MX379346B (pl)
PL (1) PL3271015T3 (pl)
RS (1) RS65039B1 (pl)
SG (1) SG11201707521QA (pl)
SI (1) SI3271015T1 (pl)
SM (1) SMT202300471T1 (pl)
WO (1) WO2016146712A1 (pl)
ZA (1) ZA201705874B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965675T3 (es) 2015-03-16 2024-04-16 Ogeda N V Antagonistas del receptor NK-3 para el tratamiento terapéutico o cosmético del exceso de grasa corporal
CN113194948A (zh) * 2018-11-15 2021-07-30 国立大学法人九州大学 Il-31介导性疾病的预防或治疗剂及医药组合物
CN112272670B (zh) * 2019-04-16 2023-12-12 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
KR20230044443A (ko) * 2020-07-30 2023-04-04 상하이 한서 바이오메디컬 컴퍼니 리미티드 질소-함유 융합된 고리 유도체 억제제, 이의 제조 방법 및 이의 용도
CN121851016A (zh) * 2021-04-21 2026-04-14 长春金赛药业有限责任公司 含咪唑稠环类衍生物、其制备方法及其在医药上的应用
CN116650481B (zh) * 2021-12-10 2024-06-14 中南大学湘雅医院 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用
WO2023147134A2 (en) * 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Methods for treating patients having low estrogen with nk3 antagonists
CN119855819B (zh) * 2022-10-19 2025-10-28 长春金赛药业有限责任公司 一种nk3r拮抗剂的晶型及其制备方法和应用
CN119968381A (zh) * 2022-10-21 2025-05-09 长春金赛药业有限责任公司 吲哚啉螺环类化合物的晶型、无定形物及二者的制备方法和应用
TW202423413A (zh) * 2022-10-21 2024-06-16 大陸商長春金賽藥業有限責任公司 吲哚啉螺環類化合物的溶劑化物及其晶型、製備方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043008A1 (en) * 1999-01-25 2000-07-27 Smithkline Beecham Corporation Anti-androgens and methods for treating disease
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
PL2552920T3 (pl) * 2010-04-02 2017-08-31 Ogeda Sa Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3
DK2763992T3 (en) * 2011-10-03 2016-04-25 Euroscreen Sa NOVEL CHIRAL N-acyl-5,6,7, (8-substituted) -tetrahydro [1,2,4] triazolo [4,3-a] pyrazines as selective NK-3 receptor antagonists, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE use in the NK-3 receptor mediated diseases
SG11201508005XA (en) 2013-03-29 2015-10-29 Euroscreen Sa NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
JP6275241B2 (ja) 2013-03-29 2018-02-07 オゲダ エス.エー. 選択的NK−3受容体拮抗薬としての新規なN−アシル−(3位置換)−5,6,7,8−テトラヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン、その医薬組成物、NK−3受容体媒介性障害で使用する方法
CA2907814C (en) 2013-03-29 2021-07-13 Euroscreen Sa Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
WO2016046398A1 (en) 2014-09-25 2016-03-31 Euroscreen Sa Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines
ES2965675T3 (es) 2015-03-16 2024-04-16 Ogeda N V Antagonistas del receptor NK-3 para el tratamiento terapéutico o cosmético del exceso de grasa corporal

Also Published As

Publication number Publication date
BR112017019829A2 (pt) 2018-05-29
JP6762312B2 (ja) 2020-09-30
US20230039022A1 (en) 2023-02-09
WO2016146712A1 (en) 2016-09-22
HUE064813T2 (hu) 2024-04-28
HRP20231661T1 (hr) 2024-03-15
EP3271015A1 (en) 2018-01-24
MX2017011937A (es) 2018-02-01
US20200222399A1 (en) 2020-07-16
US10624890B2 (en) 2020-04-21
IL254386A0 (en) 2017-11-30
AU2016232191B2 (en) 2021-07-01
RS65039B1 (sr) 2024-02-29
LT3271015T (lt) 2024-01-25
MX379346B (es) 2025-03-10
US20180289705A1 (en) 2018-10-11
IL254386B (en) 2020-09-30
KR20240033207A (ko) 2024-03-12
EA036709B1 (ru) 2020-12-10
CN107405347B (zh) 2021-05-25
EP3271015B1 (en) 2023-09-27
ES2965675T3 (es) 2024-04-16
JP2018507874A (ja) 2018-03-22
NZ734635A (en) 2024-03-22
CN107405347A (zh) 2017-11-28
EP3271015B8 (en) 2023-11-01
KR20170124566A (ko) 2017-11-10
SG11201707521QA (en) 2017-10-30
NZ773981A (en) 2024-03-22
EA201791901A1 (ru) 2018-04-30
US11478472B2 (en) 2022-10-25
AU2016232191A1 (en) 2017-08-31
FI3271015T3 (fi) 2023-12-18
SI3271015T1 (sl) 2024-02-29
SMT202300471T1 (it) 2024-03-13
CA2977444A1 (en) 2016-09-22
ZA201705874B (en) 2024-12-18
US12458641B2 (en) 2025-11-04
DK3271015T3 (da) 2024-01-02

Similar Documents

Publication Publication Date Title
IL254386B (en) NK-3 receptor antagonists for medical or cosmetic treatment of excess body fat
IL265181A (en) Breast massage bra for nursing mothers
PT3212233T (pt) Terapia combinada para o tratamento de doenças
IL270752B (en) Pyrrolopyridine-aniline compounds for the treatment of skin disorders
IL281089A (en) LINGO–1 antagonists and uses for the treatment of demyelinating disorders
GB201608046D0 (en) Treatment of complement-mediated disorders
SMT202000171T1 (it) Uso terapeutico di proteine morfogenetiche ossee
GB201611413D0 (en) Method of skin care
ZA201705847B (en) Treatment of pain
GB201612043D0 (en) Composition for treatment of disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
ZA201807692B (en) New use of product for skin treatment
EP3621619C0 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF VISCERAL PAIN
KR102594780B9 (ko) Igfbp-3 및 그것의 수용체와 관련되는 질환의 치료
ZA202002910B (en) Treatment of skin disorders
IL266243A (en) Use of senicapoc for the treatment of neuropathic pain
IL268187A (en) Use of Snickepok to treat stroke
IL234962A0 (en) Use of substances to treat fat-related diseases
PT3271015T (pt) Antagonistas do recetor nk-3 para tratamento terapêutico ou cosmético do excesso de gordura corporal
GB201604359D0 (en) Treatment of tissue disorders
HUE065063T2 (hu) Brómhexin a fájdalom kezelésére
GB201706823D0 (en) Treatment of psychological disorders
GB201621398D0 (en) Treatment of emt-associated disease
GB201504144D0 (en) Treatment of Parkinson's disease
GB201412313D0 (en) Treament of human or animal body surfaces